6,678 trials
Substance Use Disorders · Bipolar Disorder · Mood Disorders
Primary: Change in Timeline Followback of Substance Use (TLFB) — 2.3; 3.3 Days
Peri-implant Mucositis
Primary: Global Probing Depth — 2.37; 2.64 mm — p=0.28
Increased Risk of SARS-CoV-2 Infection
Primary: Negative Polymerase Chain Reaction (PCR) — 2; 7 Participants
Acne Vulgaris
Primary: Global Acne Grading System Score — 32; 30.33; 21.67; 27.5 score on a scale
Migraine
Primary: Headache Days — 5.1; 5.2 Headache days per 4 weeks
Migraine
Primary: Change in Migraine Interictal Burden Scale (MIBS-4) Scores From Baseline to Weeks 4, 8, and 12. — -1.05; -0.37; -1.71; -0.63 score on a scale
Cardiac Amyloidosis
Primary: Mean Left Ventricular Myocardial F-18 Florbetapir SUVmean — 3.2; 1.7; 5.0 ratio
Type 2 Diabetes
Primary: Change in Liver Fat Content — 14.8; 16.1; 10.7; 13.9 fat % — p=0.001
Ankylosing Spondylitis
Primary: The Proportion of Participants Who Achieved Inactive Disease Based on the Ankylosing Spondylitis Disease Activity Score (ASDAS) Measure — 9; 7 Participants
Carotid Artery Stenosis
Primary: Time to First Neurological Exam — 9; 7; 7 Minutes
Hypothyroidism;Postablative
Primary: Thyroid Stimulating Hormone (TSH) — -0.676 mIU/L — p=<0.0001
Communicable Diseases · Infection · Anti-Infective Agents
Primary: Number of Participants With Acquisition of Any New Antibiotic-resistant Organism — 9; 12 Participants
Signs and Symptoms
Primary: Sensitivity and Specificity
Type 2 Diabetes
Primary: Mean Daily Blood Glucose Concentration in Hospitalized Patients — 219.50; 218.19; 179.75; 180.67 mg/dL
Uterine Fibroids
Primary: Percentage of Participants Who Were Responders With Menstrual Blood Loss (MBL) Volume < 80 mL at Final Month and >= 50% Reduction in MBL Volume From Baseline to the…